Abstract
Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90% of total) reflects active bone destruction and a nondialyazble (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P < 0.001) and the ND urinary level (0.94 ± 0.20, P < 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 ± 0.01) was similar to that of men with no evidence of disease. For Stage D2 prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.
| Original language | English |
|---|---|
| Pages (from-to) | 117-121 |
| Number of pages | 5 |
| Journal | Cancer |
| Volume | 53 |
| Issue number | 1 |
| State | Published - Mar 1 1984 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer. / Hopkins, S. C.; Palmieri, G. M.; Niell, H. B.; Moinuddin, M.; Soloway, M. S.
In: Cancer, Vol. 53, No. 1, 01.03.1984, p. 117-121.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer
AU - Hopkins, S. C.
AU - Palmieri, G. M.
AU - Niell, H. B.
AU - Moinuddin, M.
AU - Soloway, M. S.
PY - 1984/3/1
Y1 - 1984/3/1
N2 - Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90% of total) reflects active bone destruction and a nondialyazble (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P < 0.001) and the ND urinary level (0.94 ± 0.20, P < 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 ± 0.01) was similar to that of men with no evidence of disease. For Stage D2 prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.
AB - Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90% of total) reflects active bone destruction and a nondialyazble (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P < 0.001) and the ND urinary level (0.94 ± 0.20, P < 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 ± 0.01) was similar to that of men with no evidence of disease. For Stage D2 prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.
UR - http://www.scopus.com/inward/record.url?scp=0021353141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021353141&partnerID=8YFLogxK
M3 - Article
C2 - 6689994
AN - SCOPUS:0021353141
VL - 53
SP - 117
EP - 121
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 1
ER -